Search

Displaying results 51 - 60 of 6970 in total
  1. Drug

    Fibrinogen human

    go.drugbank.com/drugs/DB09222
    ApprovedInvestigational

    It is a soluble plasma glycoprotein with a molecular weight of about 340 kDa and is a physiological substrate for three enzymes: plasmin, factor XIIIa, and thrombin. … It is indicated for the treatment of acute bleeding episodes in patients with both acquired and congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.[L41065]

    Mixtures: ARTISS SOLUTIONS FOR SEALANT, DEEP FROZEN, ARTISS - Lösungen für einen GewebekleberProducts: HAEMOCOMPLETTAN P POWDER FOR SOLUTION FOR INJECTION OR INFUSION 1G/VIAL, FIBRYGA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION OR INFUSION 1G/VIAL
  2. Drug

    Prothipendyl

    go.drugbank.com/drugs/DB12958
    Investigational

    Prothipendyl has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders.

    Products: DOMINAL 40MG UTA
  3. Drug

    Coagulation Factor IX Human

    go.drugbank.com/drugs/DB13152
    ApprovedInvestigational

    Factor IX (or Christmas factor) is one of the serine proteases of the coagulation system; it belongs to peptidase family S1. Deficiency of this protein causes hemophilia B.

    Mixtures: UMAN COMPLEX, UMAN COMPLEXProducts: IMMUNINE 120IU/ML Powder and solvent for solution for injection or infusion, REPLENINE-VF 500 FOR INJECTION
  4. Drug

    Bevacizumab

    go.drugbank.com/drugs/DB00112
    ApprovedInvestigational

    vials formulated for intravenous oncology use. … There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells.

    Categories: Experimental Unapproved Treatments for COVID-19, VEGF/VEGFR (Vascular Endothelial Growth Factor / -Receptor) inhibitorsProducts: ZIRABEV CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/4 ML, ZIRABEV CONCENTRATE FOR SOLUTION FOR INFUSION 400 MG/16 ML
  5. Drug

    Antihemophilic factor human

    go.drugbank.com/drugs/DB13192
    ApprovedInvestigational

    Antihemophilic factor human is approved by the Food and Drug Administration for use in hemophilia A (classical hemophilia) for the prevention and control of hemorrhagic episodes [FDA Label]. … Exogenous replacement of Factor VIII is currently the cornerstone of Hemophilia treatment and is used for the prophylaxis and control of bleeding episodes.

    Mixtures: Haemate P Powder and solvent for solution for injection or infusion, Haemate P 1000IU Powder and solvent for solution for injection or infusionProducts: NUWIQ POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500 IU, NUWIQ POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250 IU
  6. Drug

    Tagraxofusp

    go.drugbank.com/drugs/DB14731
    ApprovedInvestigational

    [A253762, A253887, L43702] Tagraxofusp received its first global approval by the FDA on December 21, 2018 as the first FDA-approved treatment for blastic plasmacytoid dendritic cell neoplasm, which is

    Synonyms: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
  7. Drug

    Botulinum toxin type A

    go.drugbank.com/drugs/DB00083
    ApprovedInvestigational

    [A231819,L32569] A popular use for Botox is the treatment of facial wrinkles and lines, however, there are many uses for the botulinum toxin A in the treatment of dystonia, incontinence, migraine, blepharospasm … In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use.

    Products: Powder for Solution for Injection 50 Units/Vial, Powder for Solution for Injection 200 Units/Vial
  8. Drug

    Rurioctocog alfa pegol

    go.drugbank.com/drugs/DB16007
    ApprovedInvestigational

    Factor VIII is an essential protein involved in normal blood clotting; thus, a deficient level of functional factor VIII is associated with an elevated risk for excessive bleeding caused by spontaneous

    Products: ADYNOVATE 1500IU Powder and Solvent for Solution for Injection, ADYNOVATE 2000IU Powder and Solvent for Solution for Injection
  9. Drug

    Aflibercept

    go.drugbank.com/drugs/DB08885
    ApprovedInvestigational

    [L47966,L47971] The intravitreal formulation, under the brand name EYELEA, was approved by the FDA for the treatment of retinopathy of prematurity in preterm infants in February 2023 and for the treatment … [L47976] An aflibercept biosimilar, Yesafili, was approved for use in the EU in September 2023.

    Products: ZALTRAP CONCENTRATE FOR SOLUTION FOR INFUSION 25 MG/ML, Zaltrap 25mg/ml Concentrate for Solution for Infusion
  10. Drug

    Moroctocog alfa

    go.drugbank.com/drugs/DB13999
    Approved

    Moroctocog alfa is approved by Health Canada and by the European Medicines Agency for the control and prevention of hemorrhagic episodes and for routine and surgical prophylaxis in patients with hemophilia … Exogenous replacement of Factor VIII is currently the cornerstone of Hemophilia treatment and is used for the prophylaxis and control of bleeding episodes.

    Products: Xyntha Powder and Solvent for Solution for Injection 250iu, Xyntha Powder and Solvent for Solution for Injection 500iu